The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study

SIMPLE SUMMARY: The clinical application of kinase inhibitors and immune-checkpoint inhibitors (CPI) has substantially improved the treatment landscape of melanoma. While BRAF/MEK inhibitors allow for rapid disease control, and CPI can evoke durable tumor responses, primary and secondary resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Haist, Maximilian, Stege, Henner, Ebner, Ronja, Fleischer, Maria Isabel, Loquai, Carmen, Grabbe, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101790/
https://www.ncbi.nlm.nih.gov/pubmed/35565212
http://dx.doi.org/10.3390/cancers14092082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101790/
https://www.ncbi.nlm.nih.gov/pubmed/35565212
http://dx.doi.org/10.3390/cancers14092082

Ejemplares similares